UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000031165 |
|---|---|
| Receipt number | R000035272 |
| Scientific Title | A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE) |
| Date of disclosure of the study information | 2018/02/06 |
| Last modified on | 2018/02/06 10:14:59 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)
Acronym
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)
Scientific Title
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)
Scientific Title:Acronym
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)
Region
| Japan |
Condition
Condition
locally advanced unresectable squamous cell carcinoma of the thoracic esophagus
Classification by specialty
| Gastroenterology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The aim of this randomised phase III study is to confirm the superiority of triplet combination chemotherapy that consists of 5-FU, cisplatin, and docetaxel (DCF) followed by radical surgery or definitive chemoradiotherapy comparing with standard definitive chemoradiotherapy for patients with locally advanced unresectable squamous cell carcinoma of the thoratic esophagus in overall survival
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Phase III
Assessment
Primary outcomes
overall survival
Key secondary outcomes
progression free survival, complete response proportion of chemoradiotherapy, response proportion of DCF (in case of Arm B), adverse events of DCF and chemoradiotherapy, late onset adverse events, perioperative complications (both Arm A and Arm B)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine | Maneuver |
Interventions/Control_1
A: two courses of chemotherapy with cisplatin (70 mg/m2, 2-h intravenous infusion on day 1) and 5-FU (700 mg/m2, 24-h continuous intravenous infusion on days 1-4) repeated every 4 weeks in combination with radiotherapy (a total dose of 60 Gy in a fraction of 2 Gy five times weekly) followed by two courses of additional chemotherapy with cisplatin (80 mg/m2, 2-h intravenous infusion on day 1), and 5-FU (800mg /m2, 24-h continuous intravenous infusion on days 1-5) repeated every 4 weeks. Salvage treatment can be performed in accordance with the assessment after chemoradiotherapy.
Interventions/Control_2
B: three courses of induction chemotherapy with docetaxel (70 mg/m2, 1-h intravenous infusion on day 1), cisplatin (70 mg/m2, 2-h intravenous infusion on day 1), and 5-FU (750 mg/m2, 24-h continuous intravenous infusion on days 1-5) repeated every 3 weeks, followed by conversion surgery or two courses of chemotherapy with cisplatin (70 mg/m2, 2-h intravenous infusion on day 1) and 5-FU (700 mg/m2, 24-h continuous intravenous infusion on days 1-4) repeated every 4 weeks in combination with radiotherapy (a total dose of 60 Gy in a fraction of 2 Gy five times weekly) based on the clinical evaluation. Salvage treatment can be performed in accordance with the assessment after chemoradiotherapy.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Histologically proven squamous cell carcinoma, adenosquamous carcinoma or basaloid cell carcinoma. Biopsy of accessory lesions is not mandatory.
2) Primary tumor located in thoracic esophagus (the UICC 7th edition). Tumor invading cervical or abdominal esophagus with indication of definitive radiation therapy and accessory lesions with indication of EMR are eligible.
3) Unresectable esophageal cancer based on cervical to abdominal contrast enhanced CT to fulfill either following A) or B), and patients with both unresectable supraclavicular lymph nodes and celiac artery lymph nodes metastases are ineligible.
A) cT4b or cT3 that may invade adjacent organs in accordance with UICC-TNM 7th edition and Japanese Classification of Esophageal Cancer 11th edition.
B) Other adjacent organs except esophagus are or may be invaded by regional lymph nodes or supraclavicular lymph nodes metastases.
4) No distant metastases except supraclavicular lymph nodes metastases in accordance with cervical to abdominal contrast enhanced CT. Pelvic CT is not mandatory.
5) Diagnosed by radio oncologists before register as a candidate of definitive radiotherapy in 60 Gy within the dose constraints of other organs. CT for treatment planning before register is not mandatory.
6) Aged 20 to 75 years old.
7) ECOG Performance status 0 or 1.
8) Measurable lesions not required.
9) No prior treatment for esophageal cancer except endoscopic resection.
10) No prior chemotherapy and radiotherapy for any cancer.
11) Sufficient organ functions; fulfilling all of the following conditions within 14 days;
i. Neutrophil >= 2,000/mm3
ii. Platelet >= 100,000/mm3
iii. Hb >= 9.0 g/dL
iv. T.Bil <= 1.5 mg/dL
v. AST <= 100 IU/L
vi. ALT <= 100 IU/L
vii. CCr >= 60mL/min (Cockcroft-Gault)
viii. SpO2 (room air) >=95%
12) Agreement with surgical procedure as protocol tratment if R0 esophagectomy is judged as possible.
13) Written informed consent.
Key exclusion criteria
1) Synchronous or metachronous (within 5 years) malignancy except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers.
2) Prior surgery for head and neck superficial carcinoma within 5 years.
3) Diagnosed with active infectious disease requiring systemic treatment by imaging or bacteriological inspections, and body temperature >= 38 degrees Celsius.
4) Positive for HBs antigen or HIV antigen.
5) Pregnancy, possible pregnancy, within 28 days after delivery or breast-feeding. Male subjects who want pregnancy of their partner.
6) Psychological disorder difficult to participate in this clinical study.
7) Receiving continuous systemic corticosteroid or immunosuppressant treatment.
8) Under treatment by flucytosine, phenytoin, or warfarin potassium .
9) Previous histry of allergy to iodine.
10) Diabetes mellitus uncontrollable with continuous use of insuline or hypoglycemic agents.
11) Severe emphysema or pulmonary fibrosis based on chest CT.
12) Uncontrolled arterial hypertension.
13) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration.
14) Uncontrolled valvular disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy.
Target sample size
230
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroyuki Daiko |
Organization
National Cancer Center Hospital
Division name
surgery division
Zip code
Address
5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN
TEL
03-3542-2511
hdaiko@ncc.go.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hiroki Hara |
Organization
JCOG1510 Coordinating Office
Division name
Saitama Cancer Center Department of Gastroenterology
Zip code
Address
780, Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan
TEL
048-722-1111
Homepage URL
http://www.jcog.jp/
JCOG_sir@ml.jcog.jp
Sponsor or person
Institute
Japan Clinical Oncology Group (JCOG)
Institute
Department
Personal name
Funding Source
Organization
National Cancer Center
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道大学病院(北海道)
岩手医科大学(岩手県)
東北大学病院(宮城県)
茨城県立中央病院・茨城県地域がんセンター(茨城県)
栃木県立がんセンター(栃木県)
埼玉県立がんセンター(埼玉県)
埼玉医科大学国際医療センター(埼玉県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
千葉大学医学部(千葉県)
東京歯科大学市川総合病院(千葉県)
国立がん研究センター中央病院(東京都)
東京女子医科大学(東京都)
国立病院機構東京医療センター(東京都)
慶應義塾大学病院(東京都)
昭和大学病院(東京都)
がん研究会有明病院(東京都)
虎の門病院(東京都)
東海大学医学部(神奈川県)
神奈川県立がんセンター(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
新潟大学医歯学総合病院(新潟県)
静岡県立総合病院(静岡県)
浜松医科大学(静岡県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋大学医学部(愛知県)
京都大学医学部附属病院(京都府)
大阪国際がんセンター(大阪府)
国立病院機構大阪医療センター(大阪府)
大阪急性期・総合医療センター(大阪府)
大阪市立総合医療センター(大阪府)
大阪医科大学(大阪府)
神戸大学医学部(兵庫県)
関西労災病院(兵庫県)
兵庫県立がんセンター(兵庫県)
岡山大学病院(岡山県)
広島大学病院(広島県)
広島市立安佐市民病院(広島県)
国立病院機構四国がんセンター(愛媛県)
高知医療センター(高知県)
国立病院機構九州がんセンター(福岡県)
九州大学病院(福岡県)
佐賀大学医学部(佐賀県)
熊本大学医学部(熊本県)
大分大学医学部附属病院(大分県)
鹿児島大学病院(鹿児島県)
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 02 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2017 | Year | 11 | Month | 02 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 02 | Month | 06 | Day |
Last follow-up date
| 2026 | Year | 08 | Month | 06 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 02 | Month | 06 | Day |
Last modified on
| 2018 | Year | 02 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035272
